NCT01842100

Brief Summary

Screen-and-treat approach reduces postabortal pelvic inflammatory disease after induced abortion, and at the same time alters women's sexual behavior and prevents further re-infection by sexually transmitted infections when compared to the universal antibiotic prophylaxis strategy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,193

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 1999

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 1999

Completed
6.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2006

Completed
7.2 years until next milestone

First Submitted

Initial submission to the registry

April 21, 2013

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 29, 2013

Completed
Last Updated

April 29, 2013

Status Verified

April 1, 2013

Enrollment Period

6.4 years

First QC Date

April 21, 2013

Last Update Submit

April 24, 2013

Conditions

Keywords

Induced abortionPostaboral pelvic inflammatory diseaseSexually transmitted infectionsUniversal antibiotic prophylaxisScreen-and-treat approach

Outcome Measures

Primary Outcomes (1)

  • Rate of postabortal inflammatory disease 6 weeks after induced abortion.

    6 weeks after induced abortion.

Secondary Outcomes (2)

  • Rate of re-infection by sexually transmitted infections 24 weeks after induced abortion.

    24 weeks after induced abortion.

  • Proportion of women having abstinence from sexual intercourse or using condom at 6 weeks, 24 weeks and 1 year after induced abortion.

    6 weeks, 24 weeks and 1 year after induced abortion

Study Arms (2)

Universal antibiotic prophylaxis

ACTIVE COMPARATOR

In the universal prophylaxis group, all women received doxycycline 100 mg twice daily for 7 days starting on the day of induced abortion. Screening for sexually transmitted diseases was done as baseline but the results were not revealed to the patients.

Drug: Universal antibiotic prophylaxis

Screen-and-treat

ACTIVE COMPARATOR

In the screen-and-treat group, the results of screening for sexually transmitted infections (STI) were revealed to the patients. They would only receive appropriate specific antibiotics treatment only if they were screened positive for any of the STIs. If they were found to have STI, their sexual partners would also be referred to the local social hygiene clinics for contact tracing and treatment. Contraception by barrier methods would also be advised.

Other: Screen-and-treat

Interventions

100 mg twice daily for 7 days starting on the day of induced abortion

Universal antibiotic prophylaxis

Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.

Screen-and-treat

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • women requesting for induced abortion in the gynecology clinic

You may not qualify if:

  • nil

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Queen Mary Hospital

Hong Kong, Hong Kong, China

Location

MeSH Terms

Conditions

Sexually Transmitted Diseases

Condition Hierarchy (Ancestors)

Communicable DiseasesInfectionsGenital DiseasesUrogenital DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Sofie SF Yung, MBBS, MRCOG

    The University of Hong Kong

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 21, 2013

First Posted

April 29, 2013

Study Start

September 1, 1999

Primary Completion

February 1, 2006

Study Completion

February 1, 2006

Last Updated

April 29, 2013

Record last verified: 2013-04

Locations